Alnylam Pharmaceuticals Inc. (ALNY)

80.69
NASDAQ : Health Technology
Prev Close 78.37
Day Low/High 78.77 / 81.01
52 Wk Low/High 60.27 / 124.22
Avg Volume 718.60K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 8.72B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2019 and reviewed recent business highlights.

Alnylam Announces U.S. Food And Drug Administration (FDA) Granted Priority Review Of The Givosiran New Drug Application (NDA) For The Treatment Of Acute Hepatic Porphyria

Alnylam Announces U.S. Food And Drug Administration (FDA) Granted Priority Review Of The Givosiran New Drug Application (NDA) For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.

Alnylam To Webcast Conference Call Discussing Second Quarter 2019 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2019 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2019 on Tuesday, August 6, 2019, before the U.

Alnylam Launches ONPATTRO® (patisiran) For The Treatment Of Polyneuropathy In HATTR Amyloidosis, The First-Ever RNAi Therapeutic Approved In Canada

Alnylam Launches ONPATTRO® (patisiran) For The Treatment Of Polyneuropathy In HATTR Amyloidosis, The First-Ever RNAi Therapeutic Approved In Canada

ONPATTRO ®  is the Only Treatment that Demonstrated Improvement, Relative to Baseline, in both Polyneuropathy and Quality of Life Measures in Patients 1, 2 with hATTR Amyloidosis MISSISSAUGA, ON, July 23, 2019 /CNW/ -  Alnylam Pharmaceuticals, Inc.

Alnylam And 23andMe Collaborate On MyFamily Program To Increase Awareness Of TTR-Related Hereditary Amyloidosis

Alnylam And 23andMe Collaborate On MyFamily Program To Increase Awareness Of TTR-Related Hereditary Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and 23andMe, the leading consumer genetics company, are collaborating on a program to offer free 23andMe Health + Ancestry kits to first-degree family members of 23andMe...

Alnylam Pharmaceuticals Announces Transition Of Chief Financial Officer

Alnylam Pharmaceuticals Announces Transition Of Chief Financial Officer

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Jeff Poulton is joining the Company on July 11, 2019 and has been appointed Executive Vice President and Chief Financial Officer (CFO), effective...

Alnylam Submits Marketing Authorization Application To The European Medicines Agency For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Submits Marketing Authorization Application To The European Medicines Agency For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic...

Alnylam Presents New ONPATTRO® (patisiran) Results At The 2019 Peripheral Nerve Society Annual Meeting

Alnylam Presents New ONPATTRO® (patisiran) Results At The 2019 Peripheral Nerve Society Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new results from the Global Open-Label Extension (OLE) study of ONPATTRO ® (patisiran), an RNAi therapeutic for the treatment of the polyneuropathy of...

Alnylam Announces Progress With RNAi Therapeutics Platform, Including Oral Route Of Administration And CNS And Ocular Delivery

Alnylam Announces Progress With RNAi Therapeutics Platform, Including Oral Route Of Administration And CNS And Ocular Delivery

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs...

Alnylam Announces Approval In Japan Of ONPATTRO® For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy

Alnylam Announces Approval In Japan Of ONPATTRO® For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ONPATTRO ® (patisiran) for the treatment of hereditary transthyretin-mediated...

Alnylam Completes Enrollment For ILLUMINATE-A Phase 3 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Completes Enrollment For ILLUMINATE-A Phase 3 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate...

Alnylam To Report New Clinical Results For ONPATTRO® (patisiran) At Peripheral Nerve Society (PNS) Annual Meeting And The 5th Congress Of The European Academy Of Neurology (EAN)

Alnylam To Report New Clinical Results For ONPATTRO® (patisiran) At Peripheral Nerve Society (PNS) Annual Meeting And The 5th Congress Of The European Academy Of Neurology (EAN)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present new results from the Global Open-Label Extension (OLE) study of ONPATTRO ® (patisiran) in patients with hereditary ATTR...

Alnylam Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.

Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension

Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Company's Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 10:30...

Alnylam Announces New Leadership Appointments

Alnylam Announces New Leadership Appointments

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Company's Senior Vice President (SVP), Chief Human Resources Officer (CHRO) and the promotion of Kevin...

Noteworthy Friday Option Activity: ALNY, CYRX, AKCA

Noteworthy Friday Option Activity: ALNY, CYRX, AKCA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alnylam Pharmaceuticals Inc , where a total volume of 6,797 contracts has been traded thus far today, a contract volume which is representative of approximately 679,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 46.2% of ALNY's average daily trading volume over the past month, of 1.5 million shares.

Alnylam To Webcast Presentation At Bank Of America Merrill Lynch Health Care Conference 2019

Alnylam To Webcast Presentation At Bank Of America Merrill Lynch Health Care Conference 2019

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT...

Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2019 and reviewed recent business highlights.

Alnylam To Webcast Conference Call Discussing First Quarter 2019 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2019 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2019 on Wednesday, May 1, 2019, before the U.

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran For The Treatment Of Primary Hyperoxaluria Type 1 And Presents New Positive Results From Phase 2 Open-Label Extension Study

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran For The Treatment Of Primary Hyperoxaluria Type 1 And Presents New Positive Results From Phase 2 Open-Label Extension Study

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi...

Alnylam Presents Positive Complete Results From ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Presents Positive Complete Results From ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive complete results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1...

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc.

Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration

Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam and Sanofi have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases.

Lack of Euphoria: Cramer's 'Mad Money' Recap (Tuesday 4/2/19)

Lack of Euphoria: Cramer's 'Mad Money' Recap (Tuesday 4/2/19)

The decided lack of enthusiasm for Lyft is really good for this market, says Jim Cramer. It shows investors are behaving rationally.

Mastercard, Carrizo Oil & Gas, Duluth Holdings: 'Mad Money' Lightning Round

Mastercard, Carrizo Oil & Gas, Duluth Holdings: 'Mad Money' Lightning Round

Jim Cramer weighs in on Mastercard, Carrizo Oil & Gas, Duluth Holdings, Alnylam Pharmaceuticals, United States Steel.